API | setipiprant

setipiprant Report issue

Small molecule Experimental

AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW

Setipiprant (INN; developmental code names ACT-129968, KYTH-105) is an investigational drug developed for the treatment of asthma and scalp hair loss. It was originally developed by Actelion and acts as a selective, orally available antagonist of the prostaglandin D2 receptor 2 (DP2). The drug is being developed as a novel treatment for male pattern baldness by Allergan. ^Wikipedia

Chemistry

SMILES: OC(=O)Cn1c2CCN(Cc2c3cc(F)ccc13)C(=O)c4cccc5ccccc45
InChIKey: IHAXLPDVOWLUOS-UHFFFAOYSA-N
Mol. Mass: 402.43
ALogP: 4.22 Partition coefficient
ChEMBL Molecule:
setipiprant

More Chemistry

Pharmacology

Mechanism of Action:
- Prostaglandin D2 receptor 2 (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

2-(2-(1-naphthoyl)-8-fluoro-3,4-dihydro-1h-pyrido(4,3-b)indol-5(2h)-yl)acetic acid | act-129968 | kyth-105 | setipiprant

Organizations (2)

Research & Development (2)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (4)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (4)

Alopecia (Phase 2)

Asthma (Phase 2)

Healthy Volunteers (Phase 1)

Rhinitis, Allergic, Seasonal (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 6
# of Trial Organizations: 2

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue